According to Validea's guru fundamental report, REGENERON PHARMACEUTICALS INC (REGN) receives a rating of 86% based on their Value Investor model, which is based on the strategy of Benjamin Graham. The report indicates that REGN, a large-cap value stock in the Biotechnology & Drugs industry, passes most of Graham's criteria, including sales, current ratio, low debt, long-term EPS growth and P/E ratio, but fails the price/book ratio test. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Regeneron Pharmaceuticals Inc. (REGN) has been identified by Validea's guru fundamental report as a noteworthy stock, scoring 86% based on the Value Investor model, which emulates Benjamin Graham's deep value strategy. This rating signifies a considerable interest from the model, as scores above 80% are indicative of such. REGN, a large-cap value stock within the Biotechnology & Drugs industry, successfully meets several of Graham's stringent criteria: it passed tests for sales volume, current ratio, long-term debt in relation to net current assets, long-term EPS growth, and P/E ratio. These positive attributes underscore the company's fundamental strength according to this specific value investing lens. However, REGN did not meet the criterion for the Price/Book ratio, a key metric within the Graham methodology. The overall sentiment associated with this report is moderately positive with a score of 0.55, and REGN itself carries a ticker-specific sentiment of 0.65, suggesting a favorable view based on these fundamentals, even if the immediate market impact of this specific report is rated as low (0.35).
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
